Supplements

Milk thistle: silymarin mixtures, liver claims, hepatitis C and NASH trials, product quality, and uncertain benefit

6 sources · Latest source check 2026-10-13 UTC

On this page

Milk thistle is Silybum marianum, a plant promoted for liver health and other purposes. Silymarin describes a mixture of constituents rather than a single uniform ingredient. Evidence is insufficient for definite clinical conclusions. Two NIH-supported liver trials did not establish benefit on their primary outcomes; neither a “liver cleanse” label nor an antioxidant explanation proves recovery from liver disease.[1]

Names and outcomes need definition

Names and outcomes need definition
Term	Meaning
Milk thistle	A botanical, rather than one standardized supplement.[1]
Silymarin	A mixture of plant constituents.[1]
ALT	A blood enzyme measured in the hepatitis trial.[2]
NAS	A biopsy-based disease-activity score in the NASH trial.[3]

The measured outcomes did not show a significant advantage

Between-group changes in ALT, hepatitis C RNA and quality of life did not differ significantly. Average adverse-event findings were similar. These results concern that formulation and historical eligibility; they do not diagnose current disease or compare every possible liver treatment. Full sponsor-role, rare-harm and contemporary-care appraisal remains outstanding.[2]

An enzyme response and control of infection are different outcomes

The trial measured enzymes and viral RNA separately. Improving a blood marker alone would not establish elimination of infection or prevention of cirrhosis, liver cancer or death. Its primary result was negative, and its design should not be repurposed as a personal supplement plan.[2]

Eligibility problems complicate the negative result

Central pathology review found that 49 of 78 randomized participants did not meet the histological entry criteria. That substantial classification problem limits interpretation and precision. It does not turn a negative primary result into proven benefit, or establish that every milk-thistle preparation is ineffective for every liver condition.[3]

Product-quality research asks another question

Fenclova and colleagues analyzed 26 supplements bought in US and Czech markets in 2016–2017. They found large differences in silymarin content, discrepancies with labels, batch variation and chemical or microbial contamination in the tested sample. This was an analytical product study, rather than a randomized study of patients.[4]

A historical sample is not a survey of every current product

The study supports concern about identity, labeling and contamination. It cannot establish that all products sold in 2026 have the same defects, quantify a particular user’s harm or explain every unsuccessful clinical trial. Current batch quality requires current verification; a label alone cannot transfer a trial result to a different product.[4]

Finding a contaminant does not measure its clinical consequences

Laboratory detection describes an exposure in those samples. Establishing actual illness requires additional information about amounts, use and outcomes. The authors declared no competing interests. Complete method validation, market representativeness and patient-level implications were not independently appraised here.[4]

Common effects and poorly studied situations remain relevant

NCCIH describes digestive effects including bloating, nausea and gas, and possible allergy in people sensitive to related plants such as ragweed. Pregnancy and breastfeeding safety are poorly known. Evidence for improving glucose control comes from small studies, and use to increase milk production remains unclear. Those claims require separate evidence, rather than borrowing liver-trial results.[1]

Constituents, liver injury and scarring are separate concepts

Silymarin is a mixture of flavonolignans and minor polyphenols; silybin is one constituent, rather than another name for the complete plant. The 2017 trial distinguishes steatosis, inflammation, injured liver cells and fibrosis. Steatosis means accumulated fat; fibrosis means scarring. A disease-activity score combines selected biopsy findings. These outcomes can change differently, so an improved blood enzyme or single score should not be described as proof that all liver disease has healed.[6]

A fibrosis signal deserves attention without overriding the primary result

In 99 adults with biopsy-confirmed NASH, 48 weeks of a specified silymarin regimen did not significantly improve the primary disease-activity endpoint compared with placebo:32.7% versus 26.0% reached it. More participants improved on secondary fibrosis measurements, including a one-stage biopsy reduction:22.4% versus 6.0%. The authors called for larger confirmation. Multiple outcomes and a modest sample make that encouraging signal a research question rather than established prevention of cirrhosis or liver-related death.[6]

Evidence & uncertainty

The selected trials asked different questions: blood enzymes and viral measurements versus biopsy findings. Negative results need eligibility, formulation and endpoint context; they cannot automatically settle every liver condition or preparation.[2][3]

Selected-source overview · Independent review pending

Published questions

Is silymarin one identical ingredient in every milk-thistle product?

Selected-source overview · Independent review pending. Read the evidence context.

It is a mixture, and preparations differ.[1]

Evidence behind this answer

Milk Thistle: Usefulness and Safety
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Identity, liver-evidence uncertainty, digestive/allergy effects and special-population gaps